Akeso

This study tests whether adding the experimental drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults with inoperable or metastatic disease will receive either AK11…

This study tests a new drug called AK112 in people with limited-stage small cell lung cancer whose tumors have not grown after standard chemotherapy and radiation. The drug targets two proteins (PD-1 and VEGF) to help the immune system fight cancer and cut off its blood supply. A…

This study tests whether a combination of two drugs, AK130 and AK112, can help people with advanced pancreatic cancer that has not responded to up to two prior treatments. The trial will enroll 160 participants and measure how many patients see their tumors shrink or stop growing…

This study is for people with advanced biliary tract cancer (a type of bile duct cancer) that has not responded to other treatments. It tests a combination of two drugs, AK130 and AK112, to see if they are safe and can shrink tumors. The study has two parts: first, finding the be…

This study tests whether adding extra drugs to a standard chemotherapy plus ivonescimab regimen can better shrink tumors in people with extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups. The …

This study tests a new drug called AK104 (Cadonilimab) given before and after surgery for people with a specific type of colon cancer (MSI-H/dMMR) that can be removed. The goal is to see if AK104 works better than standard chemotherapy at shrinking the tumor and preventing the ca…

This study is testing whether a combination of two experimental drugs, AK119 and AK112, can safely shrink or control advanced solid tumors that have not responded to standard treatments. About 87 adults aged 18 to 75 with various advanced cancers will receive the drug combination…

This early-phase study tests a new drug called AK146D1 in about 200 adults with advanced solid tumors that have worsened after standard treatments. The drug is designed to attach to two cancer-related targets (Trop2 and Nectin4) and deliver a toxic payload directly to tumor cells…

This study tests whether adding the drugs ivonescimab and AK117 to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 adults aged 18-75 who have not had prior treatment for their advanced cancer will be randomly assigned to receive either …

This early-stage study tests a new drug called AK138D1 in up to 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug can…

This phase 3 trial compares a new drug (AK112) plus chemotherapy against the standard treatment (bevacizumab plus chemotherapy) for people with metastatic colorectal cancer that hasn't been treated yet. About 560 adults aged 18-75 with good performance status are being recruited.…

This study tests a new drug, AK112, alone or with other treatments, for people with advanced liver cancer. The first part checks safety and the best dose, while the second part compares how well it works against standard therapies. About 280 participants will take part to see if …

This study tests whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer whose cancer has worsened after prior immunotherapy. About 536 adults aged 18–75 with good daily function will be randomly …

This study tests whether adding the drug cadonilimab to standard chemotherapy before and after surgery helps people with a certain type of esophageal cancer. About 90 adults with resectable, locally advanced esophageal squamous cell carcinoma will take part. The goal is to see if…

This study tests a combination of two experimental drugs (AK104/AK112 and TT-00420) in 100 adults with advanced liver cancer that cannot be treated with surgery. The goal is to see if the drugs can shrink tumors and control the disease. Participants must not have had prior cancer…

This study tests whether adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery helps people with stomach or gastroesophageal junction cancer live longer without the cancer coming back. About 760 adults with resectable (removable) cancer will be rando…

This study tests two experimental drugs, AK109 and AK104, with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has not responded to first-line treatment. The goal is to see if the combination can shrink tumors or slow disease prog…

This study follows up with people who have advanced stomach cancer and previously took part in trials of the drug cadonilimab. The goal is to collect long-term data on how long patients live. No new treatment is given—this is an observational study to see if the drug offers lasti…